Details of the Drug Reposition

General Information of This Drug (ID: DM2LZIY)

Drug Name
BT-061   DM2LZIY
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Asthma DISW9QNS CA23 Phase 2 [1]
Psoriasis vulgaris DIS6M7AN EA90 Phase 2 [1]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT01072383) Safety and Efficacy of Multiple Doses of BT061 in Patients With Moderate to Severe Chronic Plaque Psoriasis. U.S. National Institutes of Health.